eMultipleSclerosis Review

Pediatric multiple sclerosis. How different is the disease from adult MS? Which disease-modifying therapies have been trialed and approved for use in children? How common iscognitive impairmentin children with MS? How can it be successfully addressed?These are some of the important questions Drs.ZongqiXia andKavita Thakkarfrom theUniversity of Pittsburgh Medical Centerdiscuss in this clinically focusedeMultipleSclerosisReview podcast.Take ourpost-testto claim CME credits.To read a companion newsletterclick here.

Selectingthe most appropriateDisease Modifying Therapy (DMT)is becoming more complicated forpatients with MS and clinicians who treat them. Newer approaches and newer agents are altering the benefit/riskequation, andmaking the question ofwhich treatment ismost appropriatefor which patientmore difficult to answer. That’s the focus of our discussion with Dr.Erin Longbrake, Assistant Professor of Neurology and Director of the Multiple Sclerosis Fellowship Program at Yale University, in thiseMultipleSclerosisReview podcast. Take our post-test to claim CME credits.To read a companion newsletterclick here.

Successful management of multiple sclerosis has gone beyond slowing disease progression and preventing relapses. Improving patients’ health-related quality of life by recognizing and addressing the pervasive chronic symptoms of the disease — spasticity, fatigue, depression, cognitive dysfunction — has become increasingly important. In thiseMultipleSclerosisReview Podcast, Dr.BardiaNourbakhshfrom the Johns Hopkins School of Medicine provides clinical insight into reducing the disease burden of these common symptoms. Take our post-test to claim CME credits.To read a companion newsletterclick here.